A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis

Phase 3 Active not recruiting 443 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd

RandomizedParallel-groupTriple-blindTreatment

Summary

A multicenter, randomized, double-blind, placebo-controlled phase III clinical study of jaktinib hydrochloride tablets in the treatment of adult patients with moderate and severe atopic dermatitis

Timeline

Start: 2022-07-14
Primary completion: 2026-06
Completion: 2026-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Jaktinib	Unknown	—	Oral

A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis

Summary

Timeline

Drugs

Indications